MOLECULAR MECHANISM OF ACUTE PHASE RESPONSE: IDENTIFICATION OF SIGNAL TRANSDUCTION PATHWAYS MEDIATING CYTOKINE INHIBITORY EFFECT ON HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA (PPARα) IN LIVER CELLS

CHEW GUAT SIEW

UNIVERSITI SAINS MALAYSIA

2010

MOLECULAR MECHANISM OF ACUTE PHASE RESPONSE: IDENTIFICATION OF SIGNAL TRANSDUCTION PATHWAYS MEDIATING CYTOKINE INHIBITORY EFFECT ON HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA (PPARα) IN LIVER CELLS

by

CHEW GUAT SIEW

Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy

Sept 2010

ACKNOWLEDGEMENT

I would like to thank my supervisors, Associate Professor Dr. Tengku Sifzizul and Associate Professor Dr. Alexander Chong for their support, encouragement, invaluable help and patience throughout both the experimental work and writing of this thesis. I really appreciate you read my thesis as fast as you could.

Special thanks to Ministry of Science, Technology and Innovation (MOSTI) for supporting this research and my studentship under the E-Science Fund. A big thank you to Malaysian Toray Science Foundation (MTFS) board of directors for believing in me and supporting both my M.Sc and Ph.D research. Many thanks to all the staff of the School of Biological Sciences, especially Mr. Teoh and En. Khairul, for their much appreciated help in the cell culture lab maintenance.

I would like to take this opportunity to acknowledge the contributions and express my gratitude to the members of Lab 218, past and present, in no particular order, Dr. Chew Choy Hoong, Dr. Lim Chui Hun, Dr. Tan Mei Lan, Dr. Ooi Kheng Leong, Eng Keat, Ida Shazrina, Amir, Ann, Meng Keat, Enyu, Sze Huey, Crystal and Vani. The lesson which I have learned from their kind gestures is that research is about sharing and working together towards a better future for mankind. Thanks are also due to everybody working at the Institut Farmaseutikal dan Nutraseutikal Malaysia (IFNM), especially to Zuriati, Adelina, Faiz and Sanusi for allowing me to use their lab and printer. I dearly appreciate and thank my 'sisters', Lillian Gabriel and Siew Bee whose wisdom and unconditional love pulled me through the bumpy roads.

My heartfelt gratitude to my family, especially my husband, Eng Leong, my parents, Pa, Ma, my sister, and adorable nephew, Guat Khim and Darren for the continuous love and understanding. Finally, and most importantly, I want to thank my Lord and Saviour, Jesus Christ. He is my everything.

This thesis is dedicated to

My parents, Mr. & Mrs. Chew Seng Leong:

You have enriched my life beyond measure and I cherished you both so much

&

My husband, Eng Leong:

I find more reasons to love you everyday and I am blessed to be your wife

TABLE OF CONTENTS

		PAGE
ACKNOWLE	EDGEMENT	ii
DEDICATIO	N	iii
TABLE OF C	CONTENTS	iv
LIST OF TAI	BLES	xiv
LIST OF FIG	URES	XV
LIST OF ABI	BREVIATIONS	xxi
ABSTRAK		xxvi
ABSTRACT		xxviii
CHAPTER 1	: INTRODUCTION	
1.1	Historical background	2
1.2	Peroxisome proliferator-activated receptors (PPARs)	3
1.3	Peroxisome proliferator-activated receptor α (PPAR α)	5
1.4	Ligands of PPAR α	6
1.5	Structural organisation of PPARα	8
1.6	Physiological roles of PPARα	10
	1.6.1 PPARα and fatty metabolism	10
	1.6.2 PPARα and triglyceride-rich lipoprotein metabolism	11
	1.6.3 PPARα in inflammation, atherosclerosis and	13
	thrombosis	
1.7	Acute phase response (APR)	19
	17.1 PPARα and acute phase response	23
1.8	Cytokines and IL-6	25

	1.9	Cytok	ines signal	lling	30
	1.10	Object	tive of stud	dy	37
CHAI	PTER 2	: MAT	ERIALS A	AND METHODS	
	2.1	Mater	ials		40
	2.2	Cultur	e media aı	nd stock solutions	40
		2.2.1	Media		40
		2.2.2	Stock sol	lutions	40
		2.2.3	Host stra	in and vector	40
		2.2.4	Inhibitor	s of known signal transduction pathways	40
	2.3	Metho	ods		48
		2.3.1	Preparati	on of ceramics, glassware and plasticware	48
		2.3.2	Cell cult	ure	48
			2.3.2.1	Maintenance of cells in culture	48
			2.3.2.2	Subculturing of cells	48
			2.3.2.3	Preserving and storing of cells	49
			2.3.2.4	Thawing of frozen cells	49
			2.3.2.5	Treatment of HepG2 cells with IL-6 and	50
				inhibitors	
		2.3.3	RNA-ass	ociated techniques	50
			2.3.3.1	Isolation of total cellular RNA using Tri-	50
				Reagent LS	
			2.3.3.2	Isolation of total cellular RNA using RNeasy	51
				Total RNA Isolation kit	

	2.3.3.3	Quantitation and assessment of purity of total	52
		cellular RNA	
	2.3.3.4	Electrophoresis of RNA on denaturing	52
		agarose-formaldehyde gel	
2.3.4	Real-Tin	ne RT-PCR	53
	2.3.4.1	DNase treatment of RNA	53
	2.3.4.2	Real-Time PCR	53
2.3.5	Primers 1	used	54
2.3.6	Cloning	of PCR products	54
	2.3.6.1	Extraction of DNA from agarose	54
	2.3.6.2	Ligation of PCR fragments to pGEM-T	56
		Easy vector	
	2.3.6.3	Preparation of competent cells	56
	2.3.6.4	Transformation of competent cells	57
	2.3.6.5	PCR-screening of recombinant colonies	57
		(colony PCR)	
	2.3.6.6	Small scale preparation of plasmid DNA	58
		(Miniprep method)	
	2.3.6.7	Large-scale preparation of plasmid DNA	59
	2.3.6.8	Restriction endonuclease digestion of DNA	60
	2.3.6.9	Agarose gel electrophoresis of DNA	60
	2.3.6.10	Sequencing of the PCR products	61
2.3.7	Western	blot analysis	61
	2.3.7.1	Isolation of total cellular protein	61
	2.3.7.2	Protein assay	62

	2.3.7.3	SDS-polyacrylamide gel electrophoresis	62
		(SDS-PAGE)	
	2.3.7.4	Western blotting	64
	2.3.7.5	Immunoprobing of the blots	65
	2.3.7.6	Development of film	69
	2.3.7.7	Stripping and reprobing of membranes	69
2.3.8	Transien	t transfection analysis	70
	2.3.8.1	Lipofectin® transfection method	70
	2.3.8.2	Preparation of cell extracts	71
	2.3.8.3	Measurement of firefly luciferase activity	71
	2.3.8.4	Measurement of Renilla luciferase activity	71
	2.3.8.5	Site-directed mutagenesis	72
2.3.9	Electrop	horetic mobility shift assay (EMSA)	74
	2.3.9.1	Preparation of nuclear extracts from cells	74
	2.3.9.2	Biotin labelling of the oligonucleotides	75
	2.3.9.3	Generation of double-stranded	75
		oligonucleotides	
	2.3.9.4	The binding reaction	77
	2.3.9.5	Electrophoresis of DNA-protein complexes	77
	2.3.9.6	Electrophoretic transfer of binding reactions	77
		to nylon membrane	
	2.3.9.7	Cross-linking of the transferred DNA onto	78
		membrane	
	2.3.9.8	Detection of Biotin-labeled DNA-protein	78
		complexes by chemiluminiscence	

		2.3.9.9	Competition EMSA	79
		2.3.9.10	Antibody-supershift experiments	79
	2.3.10	Compute	r Packages	80
CHAPTER	3 : EFFI	ECTS OF 1	NHIBITORS AGAINST COMPONENTS OF	
	KNO	WN SIGN	AL TRANSDUCTION PATHWAYS OF IL-6	
	MED	DIATED A	CTION ON PPARα mRNA EXPRESSION	
3.1	Introd	luction		82
3.2	Resul	ts		85
	3.2.1	The effe	ects of IL-6 on PPARα mRNA expression in	85
		HepG2	cell line	
		3.2.1.1	Isolation of total RNA	85
		3.2.1.2	Quantification of PPARα mRNA expression	87
			by Real-Time PCR	
		3.2.1.3	The effects of IL-6 on PPARα mRNA	93
			expression	
	3.2.2	The effe	ects of inhibitors on IL-6-mediated PPARα	94
		mRNA 6	expression	
		3.2.2.1	The dose response effects of JAK-STAT	94
			inhibitors on IL-6 mediated PPAR α mRNA	
			expression	
		3.2.2.2	The dose response effects of PI3K-Akt-	98
			mTOR inhibitors on IL-6 mediated PPAR α	
			mRNA	
		3.2.2.3	The dose response effects of MAPK	104

3.3 Discussion 110

CHAPTER 4 : DETERM	INATION OF PHOSPHORYLATED COMPONENTS
OF SIGN	AL TRANSDUCTION PATHWAYS INDUCED BY IL-6
IN MEDI	ATING THE INHIBITORY EFFECT OF PPARα mRNA
EXPRESS	SION

4.1	Introd	Introduction					
4.2	Result	ts					
	4.2.1	Determi	nation of JAK-STAT pathway induced by IL-6	121			
		4.2.1.1	The time course effects of IL-6 on the	121			
			phosphorylation of the components of JAK-				
			STAT				
		4.2.1.2	The effects of JAK inhibitor on the IL-6-	126			
			mediated phosphorylation of the components				
			of JAK-STAT				
	4.2.2	Determi	nation of PI3K-Akt-mTOR pathway induced	129			
		by IL-6					
		4.2.2.1	The time course effects of IL-6 on the	129			
			phosphorylation of the components of PI3K-				
			Akt-mTOR pathway				
		4.2.2.2	The effects of PI3K, Akt and mTOR	135			
			inhibitors on the IL-6-mediated				
			phosphorylation of the components of PI3K-				
			Akt-mTOR signaling pathway				

4.2.3	Determi	nation of M	IAPK pathway induced by IL-6	143
	4.2.3.1	Determina	ation of p38 pathway induced by IL-6	144
		4.2.3.1.1	The time course effects of IL-6 on the	144
			phosphorylation of the components of p38	
			pathway	
		4.2.3.1.2	The effects of p38 inhibitors on the IL-6-	148
			mediated phosphorylation of the	
			components of p38 pathway	
	4.2.3.2	Determina	ation of ERK1/2 pathway induced by IL-6	155
		4.2.3.2.1	The time course effects of IL-6 on the	155
			phosphorylation of the components of	
			ERK1/2 pathway	
		4.2.3.2.2	The effects of ERK1/2 inhibitors on the	160
			IL-6-mediated phosphorylation	
			components of ERK1/2 pathway	
	4.2.3.3	Determina	ation of JNK pathway induced by IL-6	168
		4.2.3.3.1	The time course effects of IL-6 on the	168
			phosphorylation of the components of	
			JNK pathway	
		4.2.3.3.2	The effects of JNK inhibitors on the IL-6-	172
			mediated phosphorylation of the	
			components of JNK pathway	
4.3	Discussi	ion		177

	MEDI	ATED ACTIVITY OF THE PPARα PROMOTER			
5.1	Introdu	Introduction			
5.2	Results	Results			
	5.2.1	Determination of the effects of IL-6 on the activity of	192		
		the promoters of PPAR α			
	5.2.2	Scanning of the promoter B2 regions for putative cis-	193		
		acting elements			
	5.2.3	Analysis of the role of STAT, ATF2 and C/EBP	197		
		binding sites of PPARα promoter B2 in the IL-6-			
		treated HepG2 cells			
	5.2.4	Co-transfection experiments with the STAT1 and	201		
		STAT3 expression plasmids			
	5.2.5	The effects of specific inhibitors of STP on the	203		
		PPARα promoter B2 in the IL-6 response			
5.3	Discus	sion	208		
CHAPTER	6 : THE I	EFFECTS OF IL-6 ON STAT ACTIVATION AND			
	BIND	ING ACTIVITY			
6.1	Introdu	action	219		
6.2	Scanni	ng the mPPARγ1 promoter region for the c-Jun and			
	ATF2	binding sites	220		
	6.2.1	Electrophoretic mobility shift assay (EMSA) analysis			
		of STAT (-611/-603) region of PPARα promoter B2	220		

CHAPTER 5: DETERMINATION OF STAT IN THE EFFECTS OF IL-6

		6.2.2	Determi	nation of the specificity of the complexes	223
			produce	d with the STAT	
			(-611/-6	603) oligonucleotides	
		6.2.3	Antibod	ly-supershift experiments with the STAT	229
			(-611/-6	503) oligonucleotides	
		6.2.4	The effe	ects of inhibitors on STAT binding activity	231
			6.2.4.1	The effects of AG490 on STAT binding	231
				activity	
			6.2.4.2	The effects of Rapamycin on STAT binding	233
				activity	
			6.2.4.3	The effects of MAPK inhibitors on STAT	235
				binding activity	
	6.3	Discus	sion		237
CHA	PTER 7	: GENE	RAL DI	SCUSSION	
	7.1	Introdu	ection		248
	7.2	IL-6 an	nd the sup	pression of PPARα gene expression	249
	7.3	The sig	gnal trans	sduction pathways of IL-6 and regulation of	
		human	PPARα g	gene expression	250
	7.4	The po	ossible m	echanism for PPARα transcription repression	257
		by STA	AT transcı	ription family in IL-6 signalling	
	7.5	The re	levance o	of the IL-6-mediated repression of PPARα in	260
		human	liver ce	ells during the development of acute phase	
		respons	se		

CHAPTER 8: CONCLUSION AND FUTURE STUDIES

8.1	Conclusion	263
8.2	Future Studies	265
REFERENCE		266

LIST OF TABLES

Table	Title	Page
1.1	The PPAR α natural (endogenous) and synthetic (exogenous) ligands	7
1.2	List of cytokines important in acute phase response, their most	22
	important cellular source and biological function	
2.1	Materials used and their suppliers	41
2.2	The composition of LB Agar and LB Medium	43
2.3	Solutions for electrophoresis of DNA	43
2.4	Solutions for electrophoresis of RNA	43
2.5	Solutions for proteins and Western blot analysis	44
2.6	Genotype of E. coli strain used	44
2.7	The nature and mode of action of the inhibitors	45
2.8	The sequences of the forward and reverse primers used in Real Time	55
	PCR	
2.9	Composition of stacking and separation gels for SDS-PAGE	63
2.10	Optimized conditions for western blot analysis for different primary	66
	antibodies	
2.11	Nucleotide sequences of oligonucleotide used for site-directed	73
	mutagenesis in transient transfection analysis	
2.12	The sequences of wild-type STAT binding site and the mutated	76
	STAT binding site used in EMSA analysis	
6.1	Sequences of oligonucleotides used in EMSA analysis	226

LIST OF FIGURES

Figure	Title	Page
1.1	Schematic representation of the structural domains of PPAR	4
1.2	Schematic representation of the structural organisation of human	9
	PPARα gene	
1.3	Peroxisome proliferator-activated receptor alpha activators inhibit	15
	vascular inflammation, induce apoptosis and decrease endothelin-1	
	secretion by endothelial cells	
1.4	$\ensuremath{\text{PPAR}\alpha}$ controls vascular inflammation and thrombosis related to	18
	atherosclerosis	
1.5	Components of the acute phase response	20
1.6	Structures of IL-6 and OSM	27
1.7	Members of the IL-6-type cytokine family and their respective	29
	receptors	
1.8	Model for the JAK-STAT signal pathway	32
1.9	The PI3K/PTEN/Akt pathway	33
1.10	Classification of MAPK signalling pathway	35
2.1	Vectors used in this study. (a) pGEM-T Easy vector, (b) pGL3-	47
	Basic Vector, (c) pGL3-Control Vector, (d) pRL-TK	
3.1	The signalling cascades of IL-6 in regulating PPAR α gene	84
	expression	
3.2	Agarose-formaldehyde gel electrophoresis of total cellular RNA	86
	isolated from IL-6-treated HepG2 cells	
3.3	Graphical representation of logarithmatic scale in Real-Time RT-	88
	PCR amplification	

3.4	The universal Plaffl formula used to calculate the relative expression	90
	ratio for Real-time RT-PCR samples	
3.5	Real-Time RT-PCR standard curves	91
3.6	Graphical representation of a melting curve analysis in Real-Time	92
	RT-PCR	
3.7	Dose response of expression of PPAR α in HepG2 cells stimulated	95
	with various concentration of IL-6	
3.8	The effect of JAK-STAT inhibitor, AG490 on IL-6-mediated	97
	suppression of PPARα mRNA	
3.9a	The effect of PI3K inhibitor, Wortmannin on IL-6-mediated	99
	suppression of PPARα mRNA	
3.9b	The effect of PI3K inhibitor, LY294002 on IL-6-mediated	100
	suppression of PPARα mRNA	
3.9c	The effect of Akt inhibitor, AktIV on IL-6-mediated suppression of	102
	PPARα mRNA	
3.9d	The effect of mTOR inhibitor, Rapamycin on IL-6-mediated	103
	suppression of PPARα mRNA	
3.10a	The effect of SHP2 inhibitor, NSC87877 on IL-6-mediated	106
	suppression of PPARα mRNA	
3.10b	The effect of p38 inhibitor, SB203580 on IL-6-mediated suppression	107
	of PPARa mRNA	
3.10c	The effect of ERK inhibitor, U0126 on IL-6-mediated suppression	108
	of PPARa mRNA	
3.10d	The effect of JNK inhibitor, SP600125 on IL-6-mediated	109
	suppression of PPARα mRNA	

4.1	The proposed JAK-STAT signalling pathway in mediating IL-6	122
	suppression of PPARα mRNA expression	
4.2	Time course of the phosphorylation of STAT1 in response to IL-6	124
4.3	Time course of the phosphorylation of STAT3 in response to IL-6	125
4.4	Dose-dependent inhibition of IL-6-mediated phosphorylation of	127
	STAT by AG490	
4.5	Dose-dependent inhibition on IL-6-mediated phosphorylation of	128
	STAT3 by AG490	
4.6	The proposed PI3K-Akt-mTOR signalling pathway in mediating IL-	130
	6 suppression of PPARα mRNA expression	
4.7	Time course of the phosphorylation of PI3K in response to IL-6	131
4.8	Time course of the phosphorylation of Akt in response to IL-6	133
4.9	Time course of the phosphorylation of mTOR in response to IL-6	134
4.10	Dose-dependent inhibition of IL-6-mediated phosphorylation of	137
	STAT by AG490	
4.11	Dose-dependent inhibition of IL-6-mediated phosphorylation of Akt	138
	by Wortmannin	
4.12	Dose-dependent inhibition of IL-6-mediated phosphorylation of	140
	mTOR by AktIV inhibitor	
4.13	Dose-dependent inhibition of IL-6-mediated phosphorylation of	141
	STAT by Rapamycin	
4.14	Dose-dependent inhibition of IL-6-mediated phosphorylation of	142
	STAT by Rapamycin	
4.15	The proposed p38 signalling pathway in mediating IL-6 suppression	145
	of PPARα mRNA expression	

4.16	Time course of the phosphorylation of p38 in response to IL-6	146
4.17	Time course of the phosphorylation of ATF2 in response to IL-6	147
4.18	Dose-dependent inhibition of IL-6-mediated phosphorylation of p38	149
	by NSC878777	
4.19	Dose-dependent inhibition of IL-6-mediated phosphorylation of p38	150
	by SB203580	
4.20	Dose-dependent inhibition of IL-6-mediated phosphorylation of	152
	ATF2 by SB203580	
4.21	Dose-dependent inhibition of IL-6-mediated phosphorylation of	153
	STAT1 by SB203580	
4.22	Dose-dependent inhibition of IL-6-mediated phosphorylation of	154
	STAT3 by SB203580	
4.23	The proposed ERK1/2 signalling pathway in mediating IL-6	156
	suppression of PPARα mRNA expression	
4.24	Time course of the phosphorylation of ERK in response to IL-6	157
4.25	Time course of the phosphorylation of $C/EBP\alpha$ in response to IL-6	158
4.26	Time course of the phosphorylation of $C/EBP\beta$ in response to IL-6	159
4.27	Dose-dependent inhibition of IL-6-mediated phosphorylation of	161
	ERK by NSC 87877	
4.28	Dose-dependent inhibition of IL-6-mediated phosphorylation of	163
	ERK by U0126	
4.29	Dose-dependent inhibition of IL-6-mediated phosphorylation of	164
	C/EBPa by U0126	
4.30	Dose-dependent inhibition of IL-6-mediated phosphorylation of	165
	C/EBPβ by U0126	

4.31	Dose-dependent inhibition of IL-6-mediated phosphorylation of	166
	STAT1 by U0126	
4.32	Dose-dependent inhibition of IL-6-mediated phosphorylation of	167
	STAT3 by U0126	
4.33	The proposed JNK signalling pathway in mediating IL-6	169
	suppression of PPARα mRNA expression	
4.34	Time course of the phosphorylation of JNK in response to IL-6	170
4.35	Time course of the phosphorylation of c-Jun in response to IL-6	171
4.36	Dose-dependent inhibition of IL-6-mediated phosphorylation of	173
	JNK by NSC87877	
4.37	Dose-dependent inhibition of IL-6-mediated phosphorylation of	174
	JNK by SP600125	
4.38	Dose-dependent inhibition of IL-6-mediated phosphorylation of	175
	STAT1 by SP600125	
4.39	Dose-dependent inhibition of IL-6-mediated phosphorylation of	176
	STAT3 by SP600125	
4.40	The MAPK pathways for the IL-6-mediated suppression of $\mbox{PPAR}\alpha$	184
	in HepG2 cells	
5.1	Determination of IL-6 effect on the PPARα promoter B constructs	194
	B3 (-1147/+34), B2 (-765/+35) and B1 (-341/+34), B1a (-258/+34),	
	B1b (-164/+34), B1c (-70/+34)	
5.2	The STAT and other potential binding sites in the human $\mbox{PPAR}\alpha$	196
	promoter	
5.3	Comparison between the sequences of the mutagenesis products in	198
	(a) STAT. (b) ATF2 and (c) CEBP sites with published human	

	PPARα promoter B sequence	
5.4	Relative induction (%) of the effect of mutations in the STAT,	200
	ATF2 and C/EBP binding sites on IL-6 response activity in PPAR α	
	promoter	
5.5	The influence of STAT1 and STAT3 expression plasmids on	202
	PPARα promoter	
5.6	The effect of AG490 treatment on the activity of B2 promoter in IL-	205
	6 treated HepG2 cells	
5.7	The effect of AG490, Wortmannin, AktIV and Rapamycin treatment	206
	on the activity of B2 promoter	
5.8	The effect of NSC87877, SB203580, U0126 and SP600125	207
	treatment on the activity of B2 promoter	
6.1	Time course binding activity in response to IL-6 treatment	222
6.2	Analysis of the binding specificity of DNA-protein interactions in	224
	EMSA	
6.3	Competition experiments using mutated STAT (-549/-568)	228
	oligonucleotides	
6.4	Identification of the nature of STATs involved in DNA protein	230
	interactions using antibody-supershift assay was produced	
6.5	The effects of AG490 on the IL-6-induced STAT binding activity.	232
6.6	The effects of Rapamycin on the IL-6-induced STAT binding	234
	activity	
6.7	The effects of MAPK inhibitors on STAT binding activity	236
7.1	The elucidated signal transduction pathways mediated by IL-6 to	256

suppress PPAR α gene expression

LIST OF ABBREVIATIONS

12-HETE 12-hydroxyeicosatetraenoic acid 13-HODE 13-hydroxyoctadecadienoic acid

15-dPGJ₂ 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂ 15-HETE 15-hydroxyeicosatetraenoic acid

5'UTR 5' untranslated region

9-HODE 9-hydroxyoctadecadienoic acid

9 cis-RA
9-cis retinoic acid
AD
Activation domain
AF-1
AF-2
Activation function 1
AF-2
AP1
Activation function 2
AP1
Apo A-I
Apolipoprotein A-I

Apo A-II Apolipoprotein A-II
Apo CIII Apolipoprotein CIII

apoE Apolipoprotein E

APS Ammonium persulphate

APP Acute phase protein
APR Acute phase response

ARF6 Adipocyte differentiation-dependent regulatory factor

ATCC American Type Culture Collection

BADGE Bisphenol diglycidyl ether

BCP 1-Bromo-3-Chloropropane

bp Base pair

BSA Bovine serum albumin

C/EBP CCAAT/enhancer binding protein

CaCl₂ Calcium Chloride

CBF CCAAT-binding factor
CBP/p300 CREB binding protein
cDNA Complementary DNA

CLA-I CD-36 and LIMPII analogous 1

CO₂ Carbon dioxide

CoA Coactivators

COUP Chicken ovalbumin upstream promoter-transcription factor

CoR Corepressor

COX Cycloxygenase

CPT-I Muscle-type carnitine palmitoyltransferase type 1

CRE Cyclic AMP response element

CREB cAMP-response element binding protein

CRP C-reactive protein

DAG Diacylglycerol

dATP Deoxyadenosine triphosphate

DBD DNA-binding domain

DEPC Dietylpyrocarbonate

dCTP Deoxycytidine triphosphate

dGTP Deoxyguanosine triphosphate

DMEM Dulbecco's modified Eagle's medium

DMSO Dimethyl sulphoxide

DNA Deoxyribonucleic acid

dNTPs Deoxyribonucleoside triphosphates

DR-1 Direct repeat-1 base spacer

DTT Dithiothreitol

dTTP Deoxythymidine triphosphate

EC Endothelial cell

EDTA Ethylene diaminetetraacetic acid

EMSA Electrophoretic mobility shift assay

ERK Extracellular signal-regulated kinase

EPA Eicosapentaenoic acid

ET-1 Endothelin-1

FAT/CD36 Fatty acid translocase

FATP Fatty acid transport protein

FBS Fetal bovine serum

FXR Farnesoid-X-receptor

Gab-1 Grb2-associated binder 1

GAPDH Glyceraldehyde 3-phosphate dehydrogenase

GATE IFNy-activated transcriptional element

gp80/130 Glycoprotein 80/130

Grb2 Growth-factor-receptor-bound protein 2

H₂O Water

HAT Histone acetyltransferases

HDAC Histone deacetylase

HDL High-density lipoprotein

HMG-CoA Mitochondrial 3-hydroxy-3-methyglutaryl-CoA

HNF4 Hepatocyte nuclear factor-4

HODE Hydroxyoctadecadienoic acids

hPPARα Human peroxisome proliferator activated receptor alpha

HRP Horseradish Peroxidase

ICAM-1 Intracellular adhesion molecule-1

IFN γ Interferon gamma
IL-1 α Interleukin-1-alpha
IL-1 β Interleukin-1-beta

IL-2 Interleukin-2IL-4 Interleukin-4IL-6 Interleukin-6

INOS Inducible nitric oxide synthase

IP-10 IFNγ-inducible protein of 10 kDa

IPTG Isopropyl-β-D-thiogalactopyranoside

ISGF-RE Interferon stimulated gene factor response element

I-TAC IFN-inducible T-cell a-chemoattractant

JAK Janus kinase

JNK JUN-amino-terminal kinases

kb kilobase pairs

LAP Liver-enriched activated protein

LARII Luciferase Assay Buffer II

LB Luria-Bertani

LBD Ligand-binding domain
LDL Low density lipoprotein

LDL-R Low density lipoprotein receptor

LPL Lipoprotein lipase
LPS Lipopolysaccharide

MAPK Mitogen-activated protein kinase

MAPKK Mitogen-activated protein kinase kinases

MCP-1 Monocyte-chemoattractant protein-1

MEM/EBSS Eagle's Minimum essential medium with Earle's BSS medium

MgCl₂ Magnesium chloride

Mig Monokine induced by IFNγ

M-MLV RT Molony murine leukemia virus reverse transcriptase

MMP-9 Metalloproteinase

MOPS 3-[N-Mopholino]propanesulphonic acid

mRNA Messenger RNA

mTOR Mammalian target of rapamycin

NaCl Sodium chloride

NCBI National Center for Biotechnology Information

NF-κB Nuclear factor-κB

NSAIDs Non-steroidal anti-inflammatory drugs

OD Optical density

OxLDL Oxidized low density lipoprotein

PBP PPAR binding protein

PBS Phosphate buffered saline
PCR Polymerase chain reaction

PGC-1 PPAR gamma coactivator-1

PIAS Protein inhibitor of activated STAT

PI3K Phosphoinositide 3-Kinase

PKA Protein kinase A

PKC Protein kinase C

PLB Passive lysis buffer

PLTP Phospholipid transfer protein

PMSF Phenylmethylsufonyl fluoride

poly(dI-dC) Polydeoxyinosinic-deoxycytidylic acid

PPAR Peroxisome proliferator activated receptor

PPARα Peroxisome proliferators activated receptor alpha

PPARy Peroxisome proliferators activated receptor gamma

PPARs Peroxisome Proliferator activated receptors

PPRE Peroxisome proliferator response element

RNA Ribonucleic acid rRNA Ribosomal RNA

RT Reverse transcription
RXR Retinoic X receptor
SAA Serum amyloid A

SDS Sodium dodecyl sulphate

SH2 Src homology 2

SH2-domain-containing tyrosine phosphatase

SMC Smooth muscle cells

SMRT Silencing mediator for retinoid and thyroid hormone receptors

SOCS Suppressor of cytokine signalling

SR-A Scavenger receptor A

SRC-1 Steroid receptor coactivator 1

STAT Signal transducers and activators of transcription

SUMO Small ubiquitin related modifier

TAE Tris-acetate-EDTA

TATA Binding elelment for TATA-binding protein (TBP)

TB Terrific broth

TBP TATA box-binding protein

TBE Tris-borate-EDTA

TdT Terminal Deoxynucleotidyl Transferase

TE Tris-EDTA

TEMED N, N, N', N'-tetramethylethylenediamine

TNFα Tumour necrosis factor α

TRE TPA-response element

TZDs Thiazolidinediones

UV Ultraviolet

v/v Volume per volume

VCAM-1 Vascular cell adhesion molecule-1

VSMC Vascular smooth muscle cells

w/v Weight/volume

X-Gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside

MEKANISME MOLEKUL RANSANGAN FASA AKUT:

PENGENALPASTIAN LALU ISYARAT TRANSDUKSI YANG MEMBATAS KESAN PERENCATAN SITOKINA TERHADAP RESEPTOR AKTIVASI

MANUSIA DALAM SEL HATI

PEMBIAKAN PEROKSISOM ALPHA (PPARα)

ABSTRAK

Sitokina seperti IL-6 memainkan peranan penting dalam merangsang tindakbalas fasa akut (APR) dalam badan semasa kecederaan dan inflamasi. Dinamik ekspresi dan interaksi oleh komponen laluan isyarat dalam pengawalaturan pembiakan peroksisom alpha (PPARα) semasa APR masih belum dikenalpasti. Dalam kajian ini, kita telah mengenalpasti tiga potensi laluan isyarat, JAK-STAT, PI3K dan MAPK (p38 dan ERK1/2) yang berasas daripada komponen JAK dan SHP2 di bahagian hulu laluan IL-6, terlibat dalam merangsang perencatan pengekspresan gen PPARα. Penggunaan perencat-perencat spesifik terhadap laluan isyarat transduksi JAK, PI3K dan MAPK menunjukkan IL-6 merencat paras mRNA PPARα, melalui ransangan pengikatan STAT1 dan STAT3 ke elemen STAT pada promoter PPARa. Tambahan lagi, ekspresi lampau STAT1 dan STAT3 di dalam sel hati merencat aktiviti promoter PPARa, menunjukkan bahawa peningkatan dalam pengikatan aktiviti DNA dengan STAT merencatkan pengekspresan gen PPARα. Di samping itu, didapati bahawa rawatan dengan perencat-perencat specifik AG490, Rapamycin, SB203580 dan U0126 merencat kesan IL-6 dalam pengikatan aktiviti DNA STAT1 dan STAT3, menyarankan laluan simpang antara laluan-lalaun isyarat tersebut. Sebagai rumusan, di dalam kehadiran perencat-perencat spesifik, kesan IL-6 ke atas pengekspresan protein dan aktiviti pengikatan DNA dengan STAT1 dan STAT3 direncat secara keseluruhan atau

sebahagian. Secara keseluruhannya, kajian ini telah berjaya menemukan laluan baru yang merangsangkan perencatan pengekspresan gen PPARα oleh IL-6 yang melibatkan modulasi laluan JAK-STAT, JAK-PI3K-Akt-mTOR-STAT dan SHP-MAPK (p38-STAT dan ERK1/2-STAT). Kajian ini juga menumpukan perhatian signifikan terhadap JAK-STAT sebagai laluan dominan disebabkan laluan simpang di antara JAK-STAT dengan PI3K, dan, MAPK melalui aktivasi SHP, dan, transkripsi aktivator STAT di dalam pengawalaturan pengekspresan PPARα mRNA. Oleh itu, penentuan laluan yang mengawalatur pengekspresan PPARα di dalam sel hati yang dirawat oleh IL-6 mencadangkan keupayaan peranan fisiologi oleh PPARα memodulasi APR dan berkeupayaan mempunyai implikasi terapeutik di dalam pembentukan APR.

MOLECULAR MECHANISM OF ACUTE PHASE RESPONSE: IDENTIFICATION OF SIGNAL TRANSDUCTION PATHWAYS MEDIATING CYTOKINE-INHIBITORY EFFECT ON HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA $(PPAR\alpha) \ IN \ LIVER \ CELLS$

ABSTRACT

Cytokines, like IL-6, play an important role in triggering the acute phase response (APR) of the body to injury and inflammation. The dynamics of expression and interaction of the IL-6 signalling pathway components in the regulation of peroxisome proliferator-activated receptor alpha (PPARα) during APR remain to be properly identified. In this study, we determined that three possible potential signaling pathways, JAK-STAT, PI3K and MAPK (p38 and ERK1/2) which derived from the upstream JAK and SHP2 components of the IL-6 signalling were involved in IL-6-inhibitory effect on PPARα gene expression. Pre-treatment of cells with the pharmacological inhibitors of JAK2, PI3K and MAPK, demonstrated that IL-6 inhibited the mRNA levels of PPARα via activating the binding of STAT1 and STAT3 to STAT binding site in the PPARα promoter. Moreover, over expression of the STAT1 and STAT3 in the liver cells decreased PPARa promoter activity, indicating that an increase in DNA binding activity of STAT1 and STAT3 inhibited the PPARα gene expression. It was also found that AG490, Rapamycin, SB203580 and U0126 inhibitors attenuated the action of IL-6 on the DNA binding of STAT1 and STAT3, suggesting a cross-talk between the signaling pathways. In short, in the presence of all the inhibitors, the effect of IL-6 on protein expression and DNA binding of STAT1 and STAT3 were either completely or partially inhibited. Taken together, this study has successfully unraveled

novel pathways by which IL-6 inhibited PPAR α gene transcription, involving the modulation of JAK-STAT, JAK-associated PI3K-Akt-mTOR-STAT and SHP-mediated MAPK (p38-STAT and ERK1/2-STAT) pathways. The present study also underlines the significance of JAK-STAT as a dominant pathway due to cross-talks between JAK-STAT with PI3K, and, MAPK pathways via SHP activation, and, STAT transcription factors in down regulating the PPAR α mRNA expression. Thus, the determination of the regulatory pathways of PPAR α in IL-6-treated liver cells strongly suggests the potential physiological role for PPAR α in modulating APR and may have immediate therapeutic implications in the development of APR.

CHAPTER 1

INTRODUCTION

1.1 Historical Background

The concept of peroxisome proliferation was first initiated when Hess and his colleagues discovered that the administration of hypolipidemic drug resulted in enlarged liver or hepatomagaly which was caused by an increase in the number and size of intracellular peroxisomes (Hess *et al.*, 1965). Subsequently, a group of structurally diverse agents was found to promote and increase the number of hepatic peroxisome in rodents. Therefore, these agents are collectively named "peroxisome proliferators" (Reddy and Krishnakantha, 1975).

By 1980, Reddy and co-workers discovered that chronic, long-term administration of these chemicals to rats also resulted in liver cancer (Reddy *et al.*, 1980). These classic observations laid a foundation for the focus of future research to elucidate the mechanisms underlying the effect of peroxisome proliferators. The discovery of nuclear receptors aided this pursuit and it was soon hypothesized that the effects induced by peroxisome proliferators were the result of a receptor-mediated mechanism (Reddy and Lalwai, 1983). However, it was not until 1990 that a receptor was cloned and shown to be activated by this class of chemicals (Issemann and Green, 1990) and thus termed the peroxisome proliferator-activated receptor (PPAR).

A family of transcription factors, known as PPARs which consists of PPAR α , PPAR β / δ , PPAR γ , has moved from the status of orphan receptor to one of the best characterised nuclear receptors. Their functional characterisation provides unique insights into the role of fat in health and diseases. Recently, this nuclear receptor has also been shown to fulfil critical unique roles in general transcriptional control of numerous cellular processes, with implications in inflammation, atherosclerosis, cancer development and epidermal wound healing (Pineda-Torra *et al.*, 2002).

1.2 Peroxisome proliferator-activated receptors (PPARs)

PPARs are members of nuclear hormone receptor (NHR) superfamily, the largest family of transcription factors. There are three distinct PPAR subtypes; PPAR α (also referred to as NR1C1), PPAR β / δ (NR1C2) and PPAR γ (NR1C3), each encoded by separate genes and with specific tissue distribution pattern and metabolic functions (Issemann and Green, 1990, Dreyer *et al.*, 1992, Kliewer *et al.*, 1994, Braissant *et al.*, 1996, Pineda-Torra *et al.*, 2007).

All three PPAR isoforms possess similar structural and functional features. Principally, four functional domains have been identified which are called A/B, C, D and E/F (Figure 1.1). The N-terminal A/B domain contains a ligand-independent activation function 1 (AF-1) (Werman *et al.*, 1997) responsible for the phosphorylation of PPAR. The DNA binding domain (DBD) or C domain promotes the binding of PPAR to the peroxisome proliferator response element (PPRE) in the promoter region of target genes (Kliewer *et al.*, 1992). The D site is a docking domain for cofactors. The E/F domain or ligand-binding domain (LBD) is responsible for ligand specificity and activation of PPAR binding to the PPRE, which increases the expression of the target genes.

Prior to transcriptional activation, PPAR heterodimerises with RXR to form a complex (Kliewer *et al.*, 1992). RXRs are also members of the NHR superfamily that are activated following binding with 9 cis-RA (9-cis retinoic acid) (Desvergne and Wahli, 1999). PPAR/RXR heterodimer recognises sequences situated within the DR1 motif, whereby PPAR interacts with the upstream extended core hexamer of the DR1, whereas RXR occupies the downstream motif (Palmer *et al.*, 1995; Ijpenberg *et al.*, 1997).




Figure 1.1 Schematic representation of the structural domains of PPAR. PPAR consists of four distinct functional domains. The A/B domain is located at the N-terminal with AF-1 is responsible for phosphorylation, the domain C is implicated in DNA binding, domain D is the docking region for cofactors and domain E/F is the ligand binding domain, containing AF-2, which promotes the recruitment of cofactors required for gene transcription. AF-1, activating function-1; DBD, DNA binding domain; AF-2, activating function-2; LBD, ligand-binding domain; RXR, retinoid-X-receptor; PPRE, peroxisome proliferators response element.

1.3 Peroxisome proliferator-activated receptor α (PPAR α)

PPARα was the first PPAR to be identified (Issemann and Green, 1990). PPARα was isolated by screening a mouse liver cDNA library using a probe based on the consensus sequence of the DNA binding domain of several nuclear receptors. Full-length PPARα cDNA was found to encode a 468 amino acid protein with predicted molecular weight of 52 kDa. Analysis of the amino acid sequence demonstrated that PPARα belonged to the steroid hormone receptor superfamily since it had all the typical characteristics of steroid receptor (Evans *et al.*, 1988). The PPARα amino acid sequence displayed high homology to the DNA binding region of nuclear steroid hormone receptors such as the glucocorticoid receptor, estrogen receptor, retinoid X receptor, vitamin D receptor, thyroid receptor and retinoic acid receptor.

PPARα was also cloned from frog, rat, guinea pig and human (Wilson *et al.*, 2002). In humans and rodents, high level of PPARα mRNA is found in liver, heart, kidney and muscle. However, the mRNA level of PPARα in human liver appears lower than in rodent liver (Palmer *et al.*, 2002). In addition, it is expressed in steroidogenic tissue such as adrenals (Hierlihy *et al.*, 2006). Furthermore, human PPARα is also expressed in vascular cells including endothelial cells (Inoue *et al.*, 2001), smooth muscle cells (Staels *et al.*, 1998a; Diep *et al.*, 2006) and monocytes/macrophages (Staels *et al.*, 1998a; Chinetti *et al.*, 1998; Neve *et al.*, 2003).

In mouse and rat, PPAR α appears late in the development (Braissant and Wahli, 1998; Desvergne and Wahli, 1999). In adult rat, relatively high levels of PPAR α mRNA are detected in brown fat, liver, kidney, heart and the mucosa of stomach and duodenum. In addition, significant amounts of PPAR α mRNA are also expressed in the retina, adrenal gland, skeletal muscle and pancreatic islets (Braissant

and Wahli, 1998). Therefore, it plays an important role in the regulation of intermediary metabolism, which has been very well studied in liver. Regardless of species, the expression of PPAR α correlates with high mitochondrial and peroxisomal β -oxidation activities.

1.4 Ligands of PPARα

PPARα is a ligand-activated transcription factor. The binding of ligands to the receptor greatly increases its transcriptional activity. A diverse range of compounds which include natural (endogenous) and synthetic (exogenous) substances serve as PPARα ligands, including fatty acids and fatty acid-derived products as well as pharmacological molecules such as plasticizers and herbicides (Isseman and Green, 1990; Forman et al., 1997; Krey et al., 1997; Ward et al., 1998; Lin et al., 1999; Kota et al., 2005) (Table 1.1). The ability of PPARα to bind multiple natural and synthetic ligands is due to the structure of the ligand binding domain of PPARa. The ligand binding domain is made out of a three-dimensional fold, which consists of an antiparallel α-helical sandwich of 12 helixes (Helix 1 to Helix 12) organised in three layers with a central ligand binding hydrophobic pocket (Bourguet et al., 1995; Xu et al., 2001; Wahli, 2002). Upon ligand binding, the ligand binding pocket closes and forms a 'mouse trap model' (Wahli, 2002). Xu et al. (2006) identified the major determinant of selectivity of ligands in PPARa is the amino acid residue Tyr-314. This amino acid plays an important part in the transcriptional activation of PPARa receptor by ligands.

Table 1.1 The PPAR α natural (endogenous) and synthetic (exogenous) ligands. PPAR α can be activated by a structurally diverse group of ligands, which bind to PPAR α and increase the transcriptional activity.

Natural (Endogenous) Ligands	Synthetic (Exogenous) Ligands
Palmitic acid	Wy-14, 643
Stearic acid	Clofibrate
Oleic acid	Gemfibrozil
Linoleic acid	Nafenopin
Arachhidonic acid	Bezafibrate
Eicosapentaenoic acid	Fenofibrate
Leukotriene B4	Fenoprofen

A range of saturated and unsaturated fatty acids could activate PPARα (Gottlicher *et al.*, 1992; Burkart *et al.*, 2007). Palimitic acid, oleic acid, linoleic acid and arachidonic acid are examples of saturated acid that can activate PPARα (Banner *et al.*, 2007). Notably, PPARα is the only PPAR subtype that binds with high affinity to a wide range of saturated acids. This may be because the PPARα pocket is more lipophilic and less solvent compared to the other PPAR subtypes, explaining its selectivity for more lipophilic saturated fatty acids (Xu *et al.*, 2005). The most notable synthetic PPARα ligand is the hypolipidemic fibrates drugs. Wy-14643, clofibric acid, ciprofibrate, fenofibrate and gemfibrozil are examples of fibrates that can activate PPARα. Clofibric acid and fenofibric acid are dual activators of PPARα and PPARγ, with 10-fold selectivity for PPARα (Isseman and Green, 1990).

1.5 Structural organisation of PPARa

The human PPARα has been mapped to chromosome 22q12-q13.1 by somatic cell hybridisation and linkage analysis (Sher *et al.*, 1993). The human PPARα gene is composed of twelve exons which spanned approximately 85kb, with 5'-untranslated region coded by exons A, 1a, 2a, 2b and part of exon 3 (Vohl *et al.*, 2000; Chew *et al.*, 2003). The coding region of PPARα comprises the remainder of exon 3 and exon 4-8, with the 3'-untranslated region consisting of the last 232 bp of exon 8. The introns length vary between 0.6 kb to 20 kb as indicated in Figure 1.2.

Recently, four promoters (A, B, C, D) which are responsible in transcribing six alternatively spliced variants in the 5'-untranslated region (UTR) of human PPARα were identified (Chew *et al.*, 2003) (Figure 1.2). Promoters A and B are responsible in transcribing two variants each, while promoters C and D transcribe one variant each (Chew *et al.*, 2003; Chew *et al.*, 2007).




Figure 1.2 Schematic representation of the structural organisation of human PPARα gene. The gene spans 85 kb of genomic DNA. The spatial localisation of exons within the gene and the size of introns are indicated in the upper and lower panel respectively. Untranslated region coding regions are also indicated. Block arrows indicate the location of the four promoters A, B, C and D.

1.6 Physiological roles of PPARα

1.6.1 PPARα and fatty metabolism

PPARα serves a fundamental role in mammals by acting as a central modulator of signalling molecules that mediate changes in gene expression to maintain lipid homeostasis. PPARα is highly expressed in tissues with elevated rates of fatty acid catabolism, whereby through the interaction with PPRE on the promoter region of several genes, PPARα and its ligands regulate the transcription of the genes of key enzymes and proteins such as fatty acid transport protein (FATP), fatty acid translocase (FAT/CD36) and Acyl-CoA synthetase (ACS) that play crucial roles in the lipid and fatty acid metabolism (Schoonjans *et al.*, 1996a; Chinetti *et al.*, 2001; Ye *et al.*, 2001; van Raalte *et al.*, 2004; Israelian-Konaraki and Reaven, 2005).

Intracellular fatty acid concentrations are partly regulated by import and export system that is controlled by FATP, FAT/CD36 and ACS. These proteins facilitate the transport of fatty acids through the cell membrane and their esterification preventing their efflux (Abumrad *et al.*, 1993, Schoonjans *et al.*, 1995, Martin *et al.*, 1997, Tontonoz and Mangelsdorf, 2001).

PPARα acts as a regulator of intracellular fatty acid uptake controls. Treatment with PPARα agonists (activators) has been shown to induce FATP mRNA levels in rat liver and intestine, and induce ACS mRNA levels in liver and kidney (Schoonjans *et al.*, 1995, Martin *et al.*, 1997, Motojima *et al.*, 1998, Fruchart *et al.*, 2004). Recent experiments carried out using LDL receptor-deficient mice also showed similar induction in ACS mRNA (Srivasta *et al.*, 2006). These evidence show that PPARα activators influence fatty acid cellular uptake, which is a crucial regulatory step in lipid metabolism.

Once inside the cells, fatty acid must penetrate into the mitochondria where its metabolism takes place. Muscle-type carnitine palmitoyl transferase type I (CPT-I), a key enzyme in mitochondrial fatty acid catabolism, contains a PPRE in its promoter region and is regulated by PPARα activators (Brandt *et al.*, 1998, Mascaro *et al.*, 1998, Chinetti *et al.*, 2001, Louet *et al.*, 2001). Furthermore, activation of PPARα was proven to up-regulate the gene expression of mitochondrial 3-hydroxy-3-methyglutaryl-CoA (HMG-CoA) synthase (Rodriguez *et al.*, 1994, Meertens *et al.*, 2005). HMG-CoA synthase is a key enzyme in ketogenesis. HMG-CoA catalyses the condensation of acetyl-CoA and generates HMG-CoA, which is eventually converted into ketone bodies (Rodriguez *et al.*, 1994, Meerten *et al.*, 2005). These observations, taken together, indicate that PPARα controls fatty acid uptake, activation into acyl-CoA esters and degradation through the peroxisomal and mitochondrial β-oxidation pathways, and the synthesis of ketones (Chinetti *et al.*, 2001).

1.6.2 PPARα and triglyceride-rich lipoprotein metabolism

There is increasing evidence that serum triglycerides are strong risk factors in cardiovascular disease. One of the major effects of PPAR α activation on lipid metabolism is to reduce triglyceride-rich levels in plasma. PPAR α activators alter the synthesis and the catabolism of the trigyceride-rich lipoproteins in a way that decreases plasma triglyceride levels via induction of the lipoprotein lipase (LPL) activity (Schoonjans *et al.*, 1996b).

Schoonjans *et al.* (1996b) demonstrated that PPAR α mediates the triglyceride-lowering action of PPAR α activators by increasing lipoprotein lipase gene expression in PPRE-mediated manner. PPRE was found to be present in the human lipoprotein lipase promoter which was responsible in stimulating the expression of the gene. Two

distinct mechanisms may be involved in PPAR α induction of lipoprotein lipase activity: firstly, through the stimulation of the LPL gene expression and secondly, by the induction of hydrolytic activity of enzyme for triglyceride-rich lipoproteins secreted following treatment with PPAR α activators (Fruchart *et al.*, 1999).

Research carried out by Srivastava *et al.* (2006) further supported the above-mentioned mechanisms. A PPARα ligand, fenofibrate, was demonstrated to improve lipid abnormalities, such as lowering serum triglycerides and cholesterol, improving insulin sensitivity, and preventing accumulation of lipids in the aorta. In addition, this research showed that fenofibrate mediated its effect partly via inhibition of triglyceride production and partly via clearance of triglyceride-rich apolipoprotein B (Apo B) particles by elevating LPL and reducing apolipoprotein CIII (Apo CIII).

Apo CIII plays a key role in delaying the catabolim of triglyceride rich particles, by inhibiting their binding to the endothelial surface and lipolysis by LPL (Hertz *et al.*, 1995, Staels *et al.*, 1995, Desvergne and Wahli, 1999, Vosper *et al.*, 2007). PPARα activators were also proven to decrease Apo CIII levels, thus resulting in an enhanced lipolytic activity (Hertz *et al.*, 1995, Staels *et al.*, 1995). A few mechanisms may be involved in this negative regulation. Firstly, PPARα activators might supress Apo CIII by displacing the strong transcriptional activator of the apolipoprotein gene with a lesser active complex, resulting in lower Apo CIII promoter activity (Hertz *et al.*, 1995). Secondly, there is a possibility that PPARα activators indirectly decrease the expression of a strong transcriptional activator of the Apo CIII gene, i.e. the hepatocytes nuclear factor-4 (HNF-4) (Hertz *et al.*, 1995). Alternatively, PPARα activators may induce the expression of repressor proteins of the Apo CIII gene, such as apolipoprotein A-I regulatory protein-1, Ear3/COUP-TF or Rev-erb-alpha (Vu-Dac *et al.*, 1998, van Raalte *et al.*, 2004, Becker *et al.*, 2006).

1.6.3 PPARα in inflammation, atherosclerosis and thrombosis

Atherosclerosis is a long term process which involves recruitment and activation of different cell types, leading to inflammatory response. It is a multifactorial disease in which the occurrence of lesions may result in ischemia of the heart, brain, resulting in infarction (Zaman *et al.*, 2000).

Specifically, the process of formation of atherosclerotic plaque involves recruitment of circulating monocytes, which must first adhere to the endothelium before their invasion into vessel intima, where they subsequently develop into tissue macrophages. These macrophages accumulate intracellular lipid to become foam cells which in turn, produce cytokines and other pro-inflammatory signals, which further stimulate monocyte recruitment to the plaque. These signals also induce vascular smooth cell proliferation and invasion. Developments in the plaque will induce apoptosis of cells in the centre as well as possible plaque destabilization and rupture with subsequent thrombus formation (Vosper et al., 2002). PPARα has been widely shown to play an important role in the development of atherosclerosis (Zanbergen and Plutzky, 2007; Izzo et al., 2009). PPARα is abundantly present in the atherosclerotic lesions and in primary cultures of endothelial cells, smooth muscle cells and macrophage foam cells (Chinetti et al., 1998; Staels et al., 1998a). In addition, PPARα is present in isolated human monocyte and its expression increases upon differentiation into macrophages (Chinetti et al., 1998). Clinical studies performed showed that PPARα activators (fibrates) lower the progression of atherosclerosis in both human and animals (Hahmann et al., 1991; Fruchart et al., 1999; Fruchart, 2001; Fruchart, 2009).

Adhesion of circulating monocytes is a critical early step in atherogenesis. Marx *et al.* (1999) reported that PPAR α inhibits cytokine-induced (TNF- α) vascular cell adhesion molecule-1 (VCAM-1), an adhesion molecule critical for monocytes recruitment to atherosclerotic lesions (Marx *et al.*, 1999; Chinetti *et al.*, 2001). This strongly suggests that PPAR α may reduce the recruitment and adherance of monocyte to the endothelium. In addition, PPAR α also reduces VCAM-1 expression in endothelial cells (Chinetti *et al.*, 1998; Neve *et al.*, 2000).

In human vascular endothelial cells, PPAR α activation represses thrombin-induced expression of endothelin-1 (ET-1), a potent vasoconstrictor peptide and inducer of smooth muscle cell proliferation (Delerive *et al.*, 1999b). PPAR α activators repress the ET-1 production by interfering with AP-1 signalling pathway, which mediates thrombin activation of endothelin-1 gene transcription (Delerive *et al.*, 1999b) (Figure 1.3).

PPARα has also been implicated to interfere with transcription of several inflammatory response genes. For example, PPARα activators inhibit the expression of inducible cyclo-oxygenase-2 (COX-2) through negative interference with NFκB activation (Staels *et al.*, 1998a; Meade *et al.*, 1999). COX-2 is a catalyser of the production of prostanoids, which are major effectors of inflammation response (Paik *et al.*, 2000). In human aortic smooth muscle cells, PPARα activators inhibit interleukin-1 (IL-1)-induced secretion of interleukin-6 (IL-6) and keto prostaglandin F1-alpha (6-keto-PGF_{1-alpha}). IL-6 controls macrophages and T-cell activation, as well as vascular smooth muscle cell proliferation and migration. It also plays a major regulatory role in the acute phase response and is considered an accurate marker of vascular inflammation. IL-6 also induces the potent monocyte chemoattractant protein-1 (MCP-1) in peripheral blood mononuclear cells, which the inhibition of IL-6




Figure 1.3 Peroxisome proliferator-activated receptor alpha activators inhibit vascular inflammation, induce apoptosis and decrease endothelin-1 secretion by endothelial cells. NF κ B, Nuclear factor - κ B; AP-1, activated protein-1; IFN- γ , interferon-gamma; IKK, I κ B kinase; IL, interleukin; COX, cyclooxygenase; iNOS, inducible nitric oxide synthase; TNF α , tumour necrosis factor alpha; EC, vascular endothelial cells; SMC, vascular smooth muscle cells; M ϕ , macrophages.

will slow down recruitment of monocytes to developing plaques. PPAR α activators repress the expression of both IL-6 and 6-keto-PGF_{1-alpha} through negative cross-talk of activated PPAR α with transcriptional factors NF κ B and AP-1 signalling pathways (Staels *et al.*, 1998a; Delerive *et al.*, 1999a; Delerive *et al.*, 2001).

Recently, Neve *et al.* (2001) demonstrated that PPARα agonists inhibit tissue factor (TF) expression in human monocytes and macrophages (Neve *et al.*, 2001). Monocytic TF expression contributes to trombogenicity associated with plaque rapture and may propagate thrombus formation at the site of vascular lesions. In addition, TF also mediates adhesion and migration of monocytes (Neve *et al.*, 2001). In addition, synthetic PPARα agonist WY-14643 has been shown to reduce inducible nitric oxide synthase (iNOS) which is key inflammatory enzyme in macrophages. The inhibition by PPARα is suggested to be mediated through the modulation of the stress protein, heme oxygenase 1 (Colville-Nash *et al.*, 1998; Fruchart *et al.*, 1999).

Scavenger receptor A (SR-A) is significant in the generation of atherosclerosis plaque. It mediates the uptake of modified low-density lipoprotein (LDL) which plays key role in the formation of the foam cell (Vosper *et al.*, 2002). Matrix metalloproteinase (MMP)-9 (gelatinase B) is produced by macrophages to degrade collagen IV in the basement membrane, facilitating invasion through the vessel wall and into the intima. PPARα agonists are capable of blocking expression of both SR-A and MMP-9, and thus act in an anti-inflammatory and atherosclerotic manner (Fruchart *et al.*, 1999; Vosper *et al.*, 2002).

Finally, there is evidence that PPARα agonists are able to reduce levels of plasma pro-coagulant factors fibrinogen in human, which is an acute-phase protein whose expression is up-regulated by cytokines during inflammation (Staels *et al.*, 1998a). This, in turn, reduces the likelihood of thrombogenesis (Staels *et al.*, 1998a;

Kockx *et al.*, 1999; Vosper *et al.*, 2002). IL-6 is known to up-regulate fibrinogen expression, and it may be through the negative effects of PPARα agonists on IL-6 expression that reduces the fibrinogen levels (Castell *et al.*, 1989).

In addition, PPAR α agonists also significantly decrease plasma levels of cytokines and acute phase proteins such as C-reactive protein (CRP), which are established risk factors for cardiovascular disease. Thus, these data taken together indicate that PPAR α activators exert anti-inflammatory activities in humans (Staels *et al.*, 1998b; Chinetti *et al.*, 2001).

Therefore, PPAR α plays a novel role in atherosclerosis. PPAR α may interfere with proatherogenic processes at different levels. Firstly, PPAR α exerts beneficial effects on atherosclerosis by changing plasma lipid and lipoprotein profiles toward less atherogenic levels. Secondly, PPAR α interferes with the development of atherosclerosis by inhibiting inflammatory response at the level of vascular wall. PPAR α may interfere with the early stages of atherosclerotic lesion development by affecting monocyte recruitment by inhibiting TNF- α -induced VCAM-1 expression in endothelial cells. Furthermore, PPAR α may also influence the later stages of atherosclerosis by inducing apoptosis of activated human macrophages. In Figure 1.4, the summary of the effects PPAR α activation on vascular inflammation, atherosclerosis and thrombosis is shown (Chinetti *et al.*, 2001; Fruchart, 2009).




Figure 1.4 PPARα controls vascular inflammation and thrombosis related to atherosclerosis. CAM, cellular adhesion molecule; ET-1, endothelin-1, IL, interleukin; MCP1, monocyte chemoattractant protein; MMP, metaloproteinase; PAI-1, plasminogen activator inhibitor type 1; PG, prostaglandin, TF, tissue factor; TNF, tumour necrosis factor.

1.7 Acute phase response (APR)

The APR is a prominent systemic reaction of the organism to local or systemic disturbances in its homeostasis caused by infection, tissue injury, trauma and surgery, neoplastic growth or immunological disorders (Baumann and Gauldine, 1994; Moshage, 1997; Bengmark, 2004; Lowenstein and Matsushita, 2004; Gruys *et al.*, 2005). The APR is beneficial to the injured organism with the aim of restoring the disturbed physiological homeostasis (Moshage, 1997; Lowenstein and Matsushita, 2004; Gruys *et al.*, 2005).

There are three main components of APR, i.e. activators, regulators and effectors, as depicted in Figure 1.5. At the site of invasion by the microorganism and the place of tissue injury, a number of responses of the tissue itself are initiated. Proinflammatory cytokines which would act as activators of APR are released, and the vascular system and inflammatory cells are activated. These responses in turn are associated with production of more cytokines and other inflammatory mediators, which diffuse to the extracellular fluid compartment, circulate in the blood and bind to receptors on endothelial cells and hepatocytes, thus amplifying a local response into a systemic inflammatory response. Activators of the APR initiate an intracellular signal transduction cascade that activates the three major transcription factors (STAT3, NFκB, C/EBPβ) which alone or in combination with other proteins regulate transcription of APR effector genes. For example, previous reports have suggested a role of STAT3 in regulation of haptoglobin in liver cells. The STATs are latent transcription factors that are activated by tyrosine phosphorylation. After phosphorylation, the STAT proteins homo- or heterodimerize and translocate to the nucleus to activate the transcription of many target genes, including APPs (Darnell, 1997; Kurash et al., 2004).




Figure 1.5 Components of the acute phase response. Activated innate immune cells release activators of the APR (IL-6, TNF- α , IL-1). Activators interact with their respective receptors, inducing transcriptional regulators of the APR, including STAT3, NFκB and C/EBPβ. These transcriptional factors direct the synthesis of acute phase effector proteins, which mediate the APR. (Adapted from Lowenstain and Matsushita, 2004)

The APR is accompanied by specific changes in the concentration of plasma proteins, which would act as effectors of the APR. Proteins that increased by at least 25% during the APR are positive APP (e.g. CRP, serum amyloid A (SAA) and fibrinogen), whereas proteins that decreased are negative APPs (e.g. albumin, transferrin, and α -fetoprotein). Changes in APP concentrations are largely attributable to alterations in their rate of synthesis in the liver (Morley and Kushner, 1982; Gabey and Kushner, 1999; Khovidhunkit *et al.*, 2004).

In the liver, TNF-α, IL-1 and IL-6 play a key role in APR (Le and Vilcek, 1989; Sehgal *et al.*, 1989a; Heinrich *et al.*, 1991). These cytokines activate hepatocytic secretion of most of the APP via activating hepatocytic receptors (Le and Vilcek, 1989; Sehgal *et al.*, 1989a; Heinrich *et al.*, 2003). IL-6 is the major mediator for the hepatocytic secretion of the most of the APP (Le and Vilcek, 1989; Sehgal *et al.*, 1989b; Heinrich *et al.*, 2003). Table 1.2 shows the major cytokines involved in APR, their cellular sources and biological functions. Furthermore, it has been shown that Kupper cells play an intermediate role. After stimulation by the pro-inflammatory cytokines, the Kupper cells release IL-6 and suppress mononuclear phagocytic production of IL-1 and TNF-α (Schindler *et al.*, 1990; Gruys *et al.*, 2005), thus mitigating the whole cascade reaction. Down-regulation of the hepatocytic APR is achieved by rapid hepatic removal of circulating cytokines (Heinrich *et al.*, 1991; Heinrich *et al.*, 2003).

Table 1.2 List of cytokines important in acute phase response, their most important cellular source and biological function

Cytokine	Cellular Source	Biological Activity
IL-1α	Monocyte	Promote inflammation; activate the coagulation
IL-1β	Macrophages, B-cells	pathway; stimulate the liver to produce APP;
	and dendritic cells	catabolism of fat for energy conversion;
		stimulate the synthesis of collagen and
		collagenase for scar tissue formation; stimulate
		the synthesis of adhesion factors on endothelial
		cells and leukocytes for diapedesis; and activate
		macrophages
IL-6	Monocytes,	Stimulates the liver to produce APP; stimulates
	macrophages,	the proliferation of B-lymphocytes; antibody
	fibroblasts, Th2 cells,	production and increases neutrophil production;
	stromal cells and	induces myeloma and plasmacytoma growth;
	endothelial cells	nerve cell differentiation.
TNF-α	Monocytes,	Works synergistically with IL-1 to enhance
	macrophages, Th1 cells,	inflammation. Functions include acting on
	dendritic cells and NK	endothelial cells to stimulate inflammation and
	cells	the coagulation pathway; stimulates
		macrophages to secrete IL-1 for redundancy;
		activates neutrophils and promoting
		extracellular killing by neutrophils; stimulates
		the liver to produce APP, and acts on muscles
		and fat to stimulate catabolism for energy
		conversion

1.7.1 PPARα and acute phase response

Several studies have shown that the expression levels of APP are regulated by fibrates, which act via PPAR α dependent mechanisms (Staels *et al.*, 1998a; Gervois *et al.*, 2001; Jonkers *et al.*, 2002; Kleeman *et al.*, 2003). Several APR markers such as fibrinogen, CRP, SAA, α 2-macroglobulin and plasminogen are lowered after fenofibrate treatment in humans, whereas levels of albumin, which is a negative APR protein, is raised.

Interestingly, IL-6 effects on acute phase gene expression are fully suppressed in fenofibrate-treated wild type, but not in PPARa deficient mice (Gervois et al., 2004). The global effect of chronic PPARα activation on the expression of positive and negative acute phase genes suggests the existence of an upstream suppression of IL-6 pathway. IL-6 induces acute phase genes via a receptor system, consisting of the IL-6R (gp80) and gp130 proteins, which initiate a signaling cascade leading to downstream activation of transcription factors, such as C/EBP and STAT. In fenofibrate-treated wild-type mice, PPARα down-regulates expression levels of the IL-6R (gp80) and the signal transducer gp130 and reduces levels of phosphorylated STAT3 (Gervois et al., 2004), thus contributing to the global suppression of IL-6 induced acute phase gene transcription by PPARa agonists. Moreover, PPARa was also regulated by the expression of several key APP induced by IL-6. Even though the expression of PPARα has been found to be down-regulated by cytokines and LPS during physiological and pathophysiological changes (Beier et al., 1997; Beigneux, et al., 2000; Fang et al., 2004; Feingold et al., 2004), limited research has been carried out to look into the action of IL-6 on PPARα gene expression.

Recently, Chew *et al.* (2007) reported the molecular mechanisms by which PPARα was regulated by IL-6 in human HepG2 cells. IL-6-mediated inhibition of

PPARα gene expression was discovered to involve the activation of C/EBP isoforms. Interestingly, LPS and cytokine administration also decreases both protein and mRNA levels of PPARα in the liver of hamster and mice (Beigneux *et al.*, 2000; Beigneux *et al.*, 2002; Kim *et al.*, 2003). In addition, LPS administration significantly reduced the expression of NHR such as PPARγ, PPARβ/δ, RXR and FXR (Beigneux *et al.*, 2000; Beigneux *et al.*, 2002; Kim *et al.*, 2003; Khovidhunkit *et al.*, 2004). Therefore, these published reports strongly indicate the implication of roles played by PPARα in inflammation, lipid metabolism and atherosclerosis, which are linked to APR in the mechanisms of coordinating the regulation of multiple genes induced by cytokines.

The action of PPAR α on acute phase gene expression is not restricted to the IL-6 signalling pathway. As shown in the case of CRP, chronic activation of PPAR α also prevents IL-1 stimulation of acute phase genes such as SAA in vivo (Zambon *et al.*, 2006). PPAR α activation thus, impairs cytokine-signalling pathways in the liver, acting at different levels, resulting in a potent modulation of APR reaction. PPAR α is known to have the ability to sense intracellular lipid levels and orchestrated changes in lipid metabolism, therefore, the receptor has been recognised as liposensor (Chawla *et al.*, 2001; Khovidhunkit *et al.*, 2004).

Alterations observed in the activity of NHR liposensors are likely to play a pivotal role in the coordinated regulation of fatty acid, cholesterol metabolism and reverse cholesterol transport that occurs during the APR. The fatty acid binding protein (FABP) is well known to be down-regulated in response to infection or inflammation and is also well known target for PPARα (Memon *et al.*, 1999; Landrier *et al.*, 2004; Bornar *et al.*, 2006).

1.8 Cytokines and IL-6

Cytokines are small hormone-like proteins that play a pivotal role in the development and pathology of human disease, including diseases of the immune response. Since their discovery and cloning, it has become abundantly clear that cytokines play critical roles in regulating immune and inflammatory cells (Heinrich *et al.*, 1991). They generally act over short distances and short time spans and at very low concentrations. The most remarkable characteristics of cytokines is that they can act on cells that secrete them (autocrine action), on nearby cells (paracrine action), or in some instances on distant cells (endocrine action). It is common for different cell types to secrete the same cytokine or a single cytokine to act on several different cell types (pletotropy). Cytokines are redundant in their activity, which means that different cytokines can also stimulate a similar function in cells. Cytokines are often produced in cascade, as one cytokine stimulates its target cells to make additional cytokines. Cytokines can interact synergistically or antagonistically with each other (Heinrich *et al.*, 2003).

Cytokines have been classified (1) on the basis of their biological responses, (2) according to the receptors used or (3) according to their dimensional structures (Heinrich *et al.*, 1998). Based on the classification of their biological responses, three main groups of cytokines can be distinguished: (1) cytokines that primarily act as positive or negative growth factors for a variety of cells (IL-2, IL-3, IL-4, IL-7, IL-10, IL-11, IL-12 and granulocyte-macrophage colony stimulating factor), (2) cytokines with pro-inflammatory properties (TNF α / β , IL-1 α / β , IL-6, IFN- α / γ , IL-8, and macrophage inhibitory protein-1), and (3) factors with anti-inflammatory activity (IL-1 receptor antagonists, TNF- α binding protein and IL-1 binding protein).

Hence, IL-6 being a pro-inflammatory cytokine, plays an important role as mediator involved in the regulation of the acute-phase response to injury and infection. Besides their functions in inflammation and the immune response, IL-6 also plays a crucial role in haematopoiesis, liver and neuronal regeneration, embryonal development and fertility (Gervois *et al.*, 2004; Chang *et al.*, 2005; Song and Kellum, 2005).

IL-6 was first discovered and named interferon-β2 (IFN-β2) in 1980 by Weissenbach and colleagues (Weissenbach *et al.*, 1980) during an effort to clone and characterize the interferon-β gene in human fibroblasts. The cytokine was subsequently named B-cell stimulatory factor-2 (Hirano *et al.*, 1985), B cell differentiation factor, T cell-replacing factor, 26-kDa protein (Haegeman *et al.*, 1986), hybridoma growth factor (Brakenhoff *et al.*, 1987; Van Snick *et al.*, 1986), interleukin hybridoma plasmacytoma factor 1, plasmacytoma growth factor (Nordan *et al.*, 1987), hepatocyte-stimulating factor (Gauldie *et al.*, 1987), macrophage granulocyte-inducing factor 2, cytotoxic T cell differentiation factor (Takai *et al.*, 1988) and thrombopoietein due to its biological functions. In 1989, when these variously named proteins were found to be identical on the basis of their amino acid and/or nucleotide sequences, the name IL-6 was settled upon (Akira and Kishimoto, 1992; Song and Kellum, 2005).

IL-6 is a member of a cytokine family that consists of leukemia inhibitory factor (LIF), ciliary neurotropic factor (CNTF), IL-11, oncostatin M (OSM) and cardiotrophin 1 (CT-1). Members of this cytokine family contain four antiparallel α -helices termed A, B, C and D that are connected by two long, and one short, loops (Figure 1.6) (Heinrich *et al.*, 2003; Song and Kellum, 2005). Although each of the IL-6 type cytokine is recognized by a specific receptor complex, they all share a common